MD20140101A2 - Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer - Google Patents
Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancerInfo
- Publication number
- MD20140101A2 MD20140101A2 MDA20140101A MD20140101A MD20140101A2 MD 20140101 A2 MD20140101 A2 MD 20140101A2 MD A20140101 A MDA20140101 A MD A20140101A MD 20140101 A MD20140101 A MD 20140101A MD 20140101 A2 MD20140101 A2 MD 20140101A2
- Authority
- MD
- Moldova
- Prior art keywords
- clusterin
- inhibitor
- egfr
- cancer
- cancer cells
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to medicine, particularly to oncology, and can be used to treat cancer.According to the invention, epidermal growth factor receptor (EGFR) expression and phosphorylation is increased in cancer cells treated with anti-clusterin antibodies. Such treatment is also accompanied with the reappearance of an epithelial phenotype of the cancer cell, as determined by an increased E-cadherin expression at the surface of cancer cells. Clusterin inhibitors may thus induce reversal of the epithelial to mesenchymal phenotype and restore sensitivity of cancer cells to EGFR inhibitors. Combinations of a clusterin inhibitor and an EGFR as well as their use in the treatment of cancer are thus provided in the present invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361601786P | 2013-02-22 | 2013-02-22 | |
PCT/CA2013/000167 WO2013123588A1 (en) | 2012-02-22 | 2013-02-22 | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MD20140101A2 true MD20140101A2 (en) | 2015-02-28 |
Family
ID=52580519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDA20140101A MD20140101A2 (en) | 2013-02-22 | 2013-02-22 | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer |
Country Status (1)
Country | Link |
---|---|
MD (1) | MD20140101A2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006056054A1 (en) * | 2004-11-23 | 2006-06-01 | The University Of British Columbia | Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
WO2007030930A1 (en) * | 2005-09-13 | 2007-03-22 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
-
2013
- 2013-02-22 MD MDA20140101A patent/MD20140101A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006056054A1 (en) * | 2004-11-23 | 2006-06-01 | The University Of British Columbia | Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
WO2007030930A1 (en) * | 2005-09-13 | 2007-03-22 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021002728A (en) | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors. | |
MX2019004193A (en) | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer. | |
MX2017005553A (en) | Combination therapy for cancer. | |
PH12015502339B1 (en) | Arylquinazolines | |
MX2020008976A (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions. | |
BR112014020756A2 (en) | co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer | |
NZ628314A (en) | Cd47 antibodies and methods of use thereof | |
PH12018502570A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
CA2886946C (en) | Preeclamptic placental mesenchymal stem cell conditioned medium for use in the treatment of a tumour | |
EA201591543A1 (en) | COMBINED THERAPIES FOR CANCER TREATMENT WITH THE APPLICATION OF EGFR-TKI MICRORNA AND INHIBITORS | |
EA201590747A1 (en) | METHODS OF TREATMENT USING ADENOVIRUS | |
MX2017006015A (en) | Apilimod for use in the treatment of renal cancer. | |
PH12016500580B1 (en) | Conjugated antibodies against ly75 for the treatment of cancer | |
PH12016500753B1 (en) | Antibodies specific to fcrn | |
MX2017000142A (en) | Mesenchymal stromal cells for treating sepsis. | |
MX2019004940A (en) | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody. | |
EA201690990A1 (en) | METHODS OF OBTAINING PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | |
MX2016009655A (en) | Novel methods for treating cancer. | |
MX2021002014A (en) | Predicting breast cancer recurrence. | |
MX2014004991A (en) | Therapeutic combinations and methods of treating melanoma. | |
MX2016002720A (en) | Method for improving antibody stability. | |
EA201992875A1 (en) | T-CELLS WITH REDUCED SURFACE FUCHOSILING AND METHODS FOR PRODUCING AND USING THEM | |
TR201909632T4 (en) | Nmda antagonist prodrugs. | |
MX2020005251A (en) | Compositions for improving car-t cell functionality and user thereof. | |
MD20140101A2 (en) | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC9A | Refusal of application (patent for invention) |